β-alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial

IF 4.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Obesity Pub Date : 2025-01-12 DOI:10.1002/oby.24204

Joseph J. Matthews, Jade V. Creighton, James Donaldson, Paul A. Swinton, Ioannis Kyrou, Srikanth Bellary, Iskandar Idris, Lívia Santos, Mark D. Turner, Craig L. Doig, Kirsty J. Elliott-Sale, Craig Sale

{"title":"β-alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial","authors":"Joseph J. Matthews, Jade V. Creighton, James Donaldson, Paul A. Swinton, Ioannis Kyrou, Srikanth Bellary, Iskandar Idris, Lívia Santos, Mark D. Turner, Craig L. Doig, Kirsty J. Elliott-Sale, Craig Sale","doi":"10.1002/oby.24204","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Overweight and obesity are characterized by excess adiposity and systemic, chronic, low-grade inflammation, which is associated with several metabolic disorders. The aim of this study was to assess the feasibility and tolerability of β-alanine supplementation and to explore the effects on cardiometabolic health and cardiovascular, hepatic, and renal function in adults with overweight and obesity.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 27 adults (44% female; mean [SD], age: 58 [10] years, BMI: 31.1 [2.9] kg/m<sup>2</sup>, hemoglobin A1c: 39.8 [4.3] mmol/mol) received β-alanine (4.8 g/day) or a matched placebo for 3 months. Feasibility and tolerability outcomes included adherence, side effects, recruitment, attrition, and blinding, and exploratory outcomes included biochemical markers, blood pressures, and transthoracic echocardiography parameters. Data were analyzed using a Bayesian approach presented with 95% credible intervals (CrI).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>β-alanine was well tolerated and adhered to (adherence: placebo, 0.91 [95% CrI: 0.84–0.95]; β-alanine, 0.92 [95% CrI: 0.85–0.95]), and side effects remained at or below baseline throughout. The probability that β-alanine supplementation affected cardiometabolic, cardiovascular, or clinical biochemical outcomes was low.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Sustained-release β-alanine supplementation is well tolerated and adhered to in adults with overweight and obesity. Future research should consider more advanced metabolic conditions, which may benefit from longer duration supplementation.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 2","pages":"278-288"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774002/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24204","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Overweight and obesity are characterized by excess adiposity and systemic, chronic, low-grade inflammation, which is associated with several metabolic disorders. The aim of this study was to assess the feasibility and tolerability of β-alanine supplementation and to explore the effects on cardiometabolic health and cardiovascular, hepatic, and renal function in adults with overweight and obesity.

Methods

A total of 27 adults (44% female; mean [SD], age: 58 [10] years, BMI: 31.1 [2.9] kg/m², hemoglobin A1c: 39.8 [4.3] mmol/mol) received β-alanine (4.8 g/day) or a matched placebo for 3 months. Feasibility and tolerability outcomes included adherence, side effects, recruitment, attrition, and blinding, and exploratory outcomes included biochemical markers, blood pressures, and transthoracic echocardiography parameters. Data were analyzed using a Bayesian approach presented with 95% credible intervals (CrI).

Results

β-alanine was well tolerated and adhered to (adherence: placebo, 0.91 [95% CrI: 0.84–0.95]; β-alanine, 0.92 [95% CrI: 0.85–0.95]), and side effects remained at or below baseline throughout. The probability that β-alanine supplementation affected cardiometabolic, cardiovascular, or clinical biochemical outcomes was low.

Conclusions

Sustained-release β-alanine supplementation is well tolerated and adhered to in adults with overweight and obesity. Future research should consider more advanced metabolic conditions, which may benefit from longer duration supplementation.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

超重和肥胖成人β-丙氨酸补充：一项随机对照可行性试验

目的：超重和肥胖的特征是过度肥胖和系统性、慢性、低度炎症，这与几种代谢紊乱有关。本研究的目的是评估β-丙氨酸补充剂的可行性和耐受性，并探讨其对超重和肥胖成人心脏代谢健康和心血管、肝脏和肾脏功能的影响。方法：共27例成人(女性44%；平均[SD]，年龄：58岁，BMI: 31.1 [2.9] kg/m2，血红蛋白A1c: 39.8 [4.3] mmol/mol)接受β-丙氨酸（4.8 g/天）或匹配的安慰剂治疗3个月。可行性和耐受性结果包括依从性、副作用、招募、损耗和致盲，探索性结果包括生化指标、血压和经胸超声心动图参数。使用95%可信区间（CrI）的贝叶斯方法分析数据。结果：β-丙氨酸耐受性良好，并坚持使用(依从性：安慰剂，0.91 [95% CrI: 0.84-0.95]；β-丙氨酸，0.92 [95% CrI: 0.85-0.95])，副作用始终保持在或低于基线。β-丙氨酸补充影响心脏代谢、心血管或临床生化结果的可能性很低。结论：在超重和肥胖的成年人中，β-丙氨酸缓释补充具有良好的耐受性和依从性。未来的研究应考虑更晚期的代谢状况，这可能受益于较长时间的补充。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.